ArticleCurrent microbiology2022
In Vitro Study of the Effect of Inhibition of Quorum Sensing by Brominated Furanone on Peritoneal Dialysis-Associated Peritonitis Associated with Escherichia Coli Infection.
Article in Current microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- The Novel Chiral 2(5Molecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
In recent years, the occurrence of peritoneal dialysis (PD)-associated peritonitis (PDAP) with Escherichia coli infection has gradually increased. The presence of quorum sensing (QS) among bacteria facilitates the expansion of antibiotic resistance. Brominated furanone (BMF), a halogenated furanone compound isolated from macroalgae, is a new type of quorum-sensing inhibitor that can inhibit bacterial quorum sensing and reduce bacterial resistance. In this study, we established an in vitro peritoneal dialysis-associated peritonitis biofilm model. After intervention with BMF, the biofilm was destroyed, as shown by scanning electron microscopy, and the number of viable bacteria was reduced. Crystal violet semiquantitative determination showed that biofilm absorption significantly decreased, and RT-PCR showed that luxS expression was downregulated after drug intervention. Therefore, we propose that BMF can effectively inhibit E. coli QS by disrupting the bacterial biofilm and downregulating QS gene expression to reduce the bacterial resistance, providing a direction for the development of novel antibacterial drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.